Merck reported Q3 earnings of $0.96 per share (versus $0.9 in Q3 FY 2014), beating analysts' consensus of $0.92.
The company's revenues amounted to $10.100 bln (-4.3% y/y), in line with consensus estimate of $10.078 bln.
Merck expects FY15 EPS of $3.55-3.60 (above consensus of $3.50) and revenues of $39.2-39.8 bln (in line with consensus of $39.64 bln).
MRK rose to $53.55 (+1.21%) in pre-market trading.